MX2012003997A - Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2. - Google Patents

Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2.

Info

Publication number
MX2012003997A
MX2012003997A MX2012003997A MX2012003997A MX2012003997A MX 2012003997 A MX2012003997 A MX 2012003997A MX 2012003997 A MX2012003997 A MX 2012003997A MX 2012003997 A MX2012003997 A MX 2012003997A MX 2012003997 A MX2012003997 A MX 2012003997A
Authority
MX
Mexico
Prior art keywords
biomarkers
inhibitors
sensitivity
protein kinase
mediated diseases
Prior art date
Application number
MX2012003997A
Other languages
English (en)
Spanish (es)
Inventor
Adam Siddiqui-Jain
Denis Drygin
Caroline B Ho
Joshua R Bliesath
Kenna Anderes
Sean O'brien
William G Rice
Daniel D Vonhoff
John K C Lim
Claire S Padgett
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of MX2012003997A publication Critical patent/MX2012003997A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/575
    • G01N33/57515
    • G01N33/57555
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2012003997A 2009-10-02 2010-10-04 Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2. MX2012003997A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24827009P 2009-10-02 2009-10-02
US25580509P 2009-10-28 2009-10-28
US32377110P 2010-04-13 2010-04-13
US38068510P 2010-09-07 2010-09-07
PCT/US2010/051341 WO2011041785A1 (en) 2009-10-02 2010-10-04 Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors

Publications (1)

Publication Number Publication Date
MX2012003997A true MX2012003997A (es) 2012-07-25

Family

ID=43128291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003997A MX2012003997A (es) 2009-10-02 2010-10-04 Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2.

Country Status (11)

Country Link
US (1) US20110212845A1 (enExample)
EP (1) EP2483686A1 (enExample)
JP (1) JP2013506836A (enExample)
KR (1) KR20120104196A (enExample)
AU (1) AU2010300307A1 (enExample)
BR (1) BR112012007555B1 (enExample)
CA (1) CA2776278A1 (enExample)
IL (1) IL218935A0 (enExample)
IN (1) IN2012DN03817A (enExample)
MX (1) MX2012003997A (enExample)
WO (1) WO2011041785A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling
US9146545B2 (en) 2012-11-27 2015-09-29 Honeywell International Inc. Multivariable control system for setpoint design
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與wnt抑制劑相關之標記
KR101593595B1 (ko) * 2013-10-08 2016-02-12 한국생명공학연구원 Cx-4945를 유효성분으로 함유하는 스플라이싱 조절제
WO2015053452A1 (ko) * 2013-10-08 2015-04-16 한국생명공학연구원 Cx-4945를 유효성분으로 함유하는 스플라이싱 조절제
US20170051062A1 (en) * 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
MX375557B (es) * 2014-07-18 2025-03-06 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
WO2016133860A1 (en) * 2015-02-16 2016-08-25 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023190820A1 (ja) * 2022-03-30 2023-10-05 公立大学法人福島県立医科大学 抗CK2α抗体又はその断片
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途
KR102641010B1 (ko) * 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200715636A (en) 2005-10-04 2007-04-16 Antig Tech Co Ltd Method of controlling fuel concentration used in direct liquid fuel cell
ES2528316T3 (es) 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
US8488289B2 (en) 2006-09-27 2013-07-16 International Rectifier Corporation Current protection circuit for intelligent power switch
US20090035609A1 (en) 2007-07-31 2009-02-05 Apple Inc. Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices

Also Published As

Publication number Publication date
IN2012DN03817A (enExample) 2015-08-28
JP2013506836A (ja) 2013-02-28
BR112012007555B1 (pt) 2020-09-29
IL218935A0 (en) 2012-07-31
US20110212845A1 (en) 2011-09-01
WO2011041785A1 (en) 2011-04-07
BR112012007555A2 (pt) 2016-10-25
CA2776278A1 (en) 2011-04-07
EP2483686A1 (en) 2012-08-08
KR20120104196A (ko) 2012-09-20
AU2010300307A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
MX2012003997A (es) Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2.
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
PH12012501581A1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
WO2011022436A3 (en) Computer-automated spatial analysis
EA201071324A1 (ru) Система и способы измерения профилей биомаркеров
UA118658C2 (uk) СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
EP3190416A4 (en) Biomarker for predicting sensitivity to protein kinase inhibitor and use thereof
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
WO2012135749A3 (en) Biomarkers for predicting sensitivity to cancer treatments
BR112015013771A2 (pt) biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal